Alderaan Biotechnology presents latest developments at SITC Congress

Alderaan Biotechnology presents latest developments at SITC Congress

Alderaan Biotechnology presents latest developments at SITC Congress 329 293 gloria

Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress.

  • ALD2510 antibody shows promising tolerability and efficacy results for treatment of gynecologic and breast cancers
  • Preclinical results to be presented during SITC congress on November 8-12, in Boston, MA

Read More